The current status of adjuvant hormonal therapy combined with radiation therapy for localised prostate cancer (Record no. 7346)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01573 am a2200169 4500 |
| 001 - CONTROL NUMBER | |
| control field | 2137 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Terms of availability | 0.00 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Irish Journal of Medical Science, Volume 167, Issue 3, Pages 138 - 144, 1998, |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | Publications Archive ARMS |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Armstrong, John, G. |
| 9 (RLIN) | 32546 |
| 245 ## - TITLE STATEMENT | |
| Title | The current status of adjuvant hormonal therapy combined with radiation therapy for localised prostate cancer |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 1998. |
| 490 ## - SERIES STATEMENT | |
| Series statement | Staff Publications |
| Volume/sequential designation | Staff Publications- Armstrong, John |
| 500 ## - GENERAL NOTE | |
| General note | The print version of this article is held in the Oncology Resource Centre. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Analysis of the results of treatment of localised prostate cancer with radiation and surgery has identified patients who are at high risk of developing metastatic dissemination. High histologic grade, serum prostate specific antigen above 20 ng/ml, extension beyond the capsule of the prostate, and involvement of lymph nodes are highly predictive of metastatic risk. Antiandrogen therapy has high rates of activity in the treatment of overt metastatic disease prompting its assessment as an adjuvant treatment added to radiation therapy. There are now major prospective randomized trials which have been completed. The current evidence indicates that a large survival benefit ensues when antiandrogen therapy is added to radiation for appropriately selected patients. This adjuvant approach is likely to become the standard of care. Strategies for further enhancement of adjuvant therapy are discussed. |
| 9 (RLIN) | 34971 |
| 710 ## - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | ST. LUKE'S PUBLICATION ARCHIVE |
| 9 (RLIN) | 32511 |
| Withdrawn status | Lost status | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Cost, normal purchase price | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Withdrawn | Not Lost | Not Damaged | Available for Loan | St. Luke’s Radiation Oncology Network Dublin | St. Luke’s Radiation Oncology Network Dublin | AR | 14/05/2018 | 0.00 | PUBLICATIONS ARCHIVE ARMS | 39015000018328 | 14/05/2018 | 14/05/2018 | 2 Week Loan |